Thesis icon

Thesis

HR23B, a biomarker for HDAC inhibitors

Abstract:

As our understanding of cancer biology increases and novel therapies are developed, an increasing number of predictive biomarkers are becoming clinically available. Aberrant acetylation has been strongly linked to tumourigenesis and the modulation of acetylation through targeting histone deacetylase (HDAC) has led to the introduction of many HDAC inhibitors. To date, two have had regulatory approval for the treatment of cutaneous T cell lymphoma (CTCL). Modifications in chromatin control...

Expand abstract

Actions


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Pharmacology
Research group:
La Thangue
Oxford college:
Linacre College
Role:
Author

Contributors

Division:
MSD
Department:
Pharmacology
Role:
Supervisor
Publication date:
2013
Type of award:
DPhil
Level of award:
Doctoral
Awarding institution:
University of Oxford
Language:
English
Keywords:
Subjects:
UUID:
uuid:9cd76c0b-e70e-43f7-a92d-a99f403a077e
Local pid:
ora:8911
Deposit date:
2014-09-10

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP